3 New Articles on Hepatitis C Treatment

[Guest guest]

HIVandHepatitis.com

European Committee Recommends Boceprevir (Victrelis)

SUMMARY

The European Medicines Agency's Committee for Medicinal Products for Human Use

has recommended approval of the HCV protease inhibitor boceprevir (brand name

Victrelis) for treatment of chronic hepatitis C.

TMC435 Boosts Hepatitis C Post-Treatment Response

SUMMARY

Genotype 1 hepatitis C patients who added the experimental HCV protease

inhibitor TMC435 to pegylated interferon/ribavirin were more likely to

experience sustained response 4 weeks after treatment completion than those

using standard therapy alone.

Quality of Life for Children on Hepatitis C Treatment

SUMMARY

Children treated with pegylated interferon plus ribavirin or placebo experienced

some worsening of physical symptoms after starting therapy, but most had no

clinically significant changes in quality of life or emotional and cognitive

functioning by the end of treatment.